Sonoma Pharmaceuticals (SNOA) Return on Invested Capital (2016 - 2026)

Sonoma Pharmaceuticals' Return on Invested Capital history runs 10 years deep, the most recent figure standing at 0.05% for Q1 2026.

• In Q1 2026, Return on Invested Capital rose 2.0% year-over-year to 0.05%; the TTM figure through Mar 2026 stood at 0.05% (up 2.0% YoY), while the FY2026 annual figure was 0.1%, up 6.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.05%, up from 0.07% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.02% in Q1 2022, with the low at 0.09% in Q2 2025.
• The 5-year median for Return on Invested Capital is 0.05% (2026), against an average of 0.05%.
• The sharpest annual moves came in 2022 and 2023: Return on Invested Capital grew 3 bps in 2022, then declined 3 bps in 2023.
• Sonoma Pharmaceuticals' Return on Invested Capital stood at 0.04% in 2022, then declined by 13 bps to 0.05% in 2023, then plunged by 49 bps to 0.07% in 2024, then rose by 8 bps to 0.07% in 2025, then rose by 16 bps to 0.05% in 2026.
• Business Quant data shows SNOA's Return on Invested Capital at 0.05% in Q1 2026, 0.07% in Q4 2025, and 0.07% in Q3 2025.